Recurrent driver mutations in HBs are already well-established, such as mutations in the Wnt pathway genes, mainly CTNNB1, and mutations in NFE2L2 and the promoter of TERT. It is hard to establish which of the novel mutations have impact in tumor development due to the variability of the mutational profiles of the tumors, and probably only part of the alterations is actually relevant for HB biology. Here, NFE2L2 is linked to hemoglobin measurement.